Early study of a new treatment for autoimmune disease
Part of Immune system & allergy clinical trials.
This study tests a new treatment (STR-P005) for autoimmune diseases. It aims to selectively target and deplete B cells that carry a specific marker, CD19, which may help reduce disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your B cells must show a marker called CD19, which the study treatment targets.
- Your heart, lungs, liver, kidneys, and blood counts need to be in decent shape.
- You must not have had certain cell-based treatments before, unless they've cleared your system.
- You must be able to stop certain immune-suppressing or B-cell-depleting medications before joining.
- You cannot be pregnant or breastfeeding, and you must avoid live vaccines around the treatment time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called STR-P005 for people with diseases that affect B cells, such as certain autoimmune or blood disorders. The goal is to see if the drug is safe and if it helps reduce your disease symptoms.
This trial tests a new medicine called STR-P004 for people with kidney diseases caused by the immune system attacking the kidneys. The study checks if the medicine is safe and if the body can tolerate it, which may help reduce kidney damage.
This early-phase trial tests an experimental drug called STR-P004 in people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. The goal is to check the drug's safety and see if it helps shrink or control the lymphoma.
This trial tests a new drug called STR-P004 for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), a type of blood cancer. The goal is to see if the drug is safe and can help shrink or control the cancer.
This study tests a new drug called RXIM002 for people with severe autoimmune diseases that haven't improved with standard treatments. It aims to see if targeting immune cells with the CD19 marker can help control the disease.
This trial tests the safety of a new treatment called STR-P004 for people with systemic lupus erythematosus (SLE) or certain inflammatory muscle diseases that have not improved with standard therapies. It may be an option if your condition is hard to control.
Hear when a new Relapsed/Refractory Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.